Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has announced that Elaprase, a human enzyme replacement therapy for the treatment of Hunter syndrome, has received approval from the Brazilian Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria.
Subscribe to our email newsletter
Elaprase, developed by Shire Human Genetic Therapies (HGT), a business unit of Shire focused on genetic diseases, is said to be the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. With this approval, Elaprase is now cleared for marketing in two countries in Latin America – Brazil and Mexico.
Sylvie Gregoire, president of Shire HGT, said: “Approval of Elaprase in Brazil further demonstrates our commitment to bringing meaningful treatments to patients across Latin America – and the world.”